Reforming America’s Healthcare System Through Choice and Competition

whitePaper | February 3, 2023

Since the beginning of the COVID-19 pandemic, pharmaceutical organizations have experienced major changes, a prime example of which has been the rising requirement for collaborations on multiple different fronts across the industry.

whitePaper | April 1, 2021

Every year, the U.S. pharmaceutical industry develops a variety of new drugs that provide valuable medical benefits. Many of those drugs are expensive and contribute to rising health care costs for the private sector and the federal government. Policymakers have considered policies that would lower drug prices and reduce federal drug expenditures. Such policies would probably reduce the industry’s incentive to develop new drugs.

whitePaper | August 8, 2022

Biopharma R&D professionals generally admit that the current "high-cost, high-risk" development model is unsustainable. Despite technological.

whitePaper | February 28, 2022

Starting in Week 9 of 2020, prescription volume and claims data entered a period of intense volatility, followed by a steady state

whitePaper | November 19, 2022

In the second year of the pandemic, dealmaking continued to take place at record levels, maintaining much of the momentum created during 2020.

whitePaper | May 18, 2022

Post-COVID conditions, also known by such terms as long COVID and post-acute sequelae of COVID-19, have become an issue of growing national concern.